To foster Hong Kong’s biomedical technologies, AstraZeneca and the HKSTP have launched the captioned programme. Funding Support of up to HK$6 millionSuccessful applicants of the programme will be eligible to a series of professional support from HKSTP, including the funding support of up to HK$6 million, working space and advanced laboratory facilities, as well as leverage HKSTP’s value-added services platform which provides business matching opportunities with strategic partners and potential investors, and talent support. Albert Wong, CEO of HKSTP, said: “Biomedical technology is a key strategic focus for HKSTP. This partnership between HKSTP and AstraZeneca marks a key milestone in HKSTP’s mission to continually drive Hong Kong’s biomedical technology development. It is hoped that these networks can be fully utilized to create opportunities for HK biomedical startups, and eventually benefiting local and even global cancer patients.

Source: The Standard February 23, 2021 02:37 UTC